Condition
Metastatic Medullary Thyroid Cancer
Total Trials
4
Recruiting
0
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 2 (1)
Trial Status
Completed3
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04877613Phase 1Active Not RecruitingPrimary
GFRα4 CAR T Cells in MTC Patients
NCT00654238Phase 2Completed
Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
NCT01927887Not ApplicableCompleted
Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study
NCT02109250CompletedPrimary
CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice
Showing all 4 trials